# NCT04656652 (NCT04656652)

> Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04656652
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Non-small Cell Lung Cancer
- Interventions: DS-1062a; Docetaxel
- Enrollment: 605
- Primary outcome: Progression-free Survival (PFS) As Assessed by Blinded Independent Central Review (BICR) Per RECIST v1.1 Following DS-1062a Versus Docetaxel
- Primary outcome: Overall Survival (OS) Following DS-1062a Versus Docetaxel

## Commentary we found

- X threads: 116
- Podcasts: 81
- YouTube: 79
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct04656652

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04656652", "email": "<work email>"}; the inbox owner confirms by the emailed link.